Fresenius Kabi Receives FDA Warning Letter After Aseptic Processing Investigation Failures at Melrose Park Facility

Repeated failures to investigate aseptic processing deviations adequately have placed Fresenius Kabi AG under formal FDA scrutiny, with a warning letter issued September 22, 2026, following an inspection of its Melrose Park, Illinois sterile injectables site that ran from January 27 to February 18, 2026. The letter, addressed to CEO Pierluigi Antonelli, cites adulteration under section 501(a)(2)(B) of the FD&C Act and signals that batch release decisions at the facility were not supported by defensible root-cause analysis.

The core violation under 21 CFR 211.192 centers on investigation quality, not isolated test failures. FDA found that multiple investigations lacked data-supported root causes, failed to expand scope to all potentially affected products, and relied inappropriately on passing finished-product sterility and endotoxin results to close deviations without formal CAPA effectiveness checks. For QA directors, this is a direct signal that end-product testing cannot substitute for process-level investigation rigor.

The famotidine for injection program illustrates the compounding risk. The facility recorded multiple bioburden action-limit failures during 2025 and 2026 manufacturing campaigns, yet batches were released following passing sterility and endotoxin results. Adverse event reports of apparent pyrogenic reactions in patients subsequently prompted retesting of finished-product retains, which returned an endotoxin failure. Three famotidine batches were ultimately recalled. The sequence demonstrates how an over-reliance on release testing, absent a thorough deviation investigation, can allow a sterility assurance breakdown to reach patients before it is detected.

For plant heads managing sterile injectable lines, the inspection record reinforces that FDA's CGMP expectations under 21 CFR Parts 210 and 211 require investigations to be prospective and systemic, not retrospective and batch-specific. Environmental monitoring excursions and bioburden action-limit failures must trigger formal root-cause analysis and cross-product scope assessments regardless of whether finished-product release tests pass. The agency's explicit rejection of Fresenius Kabi's March 11, 2026 FDA 483 response underscores that corrective commitments lacking effectiveness verification will not satisfy CDER reviewers.

Regulatory affairs leads should note that the warning letter leaves open the possibility of seizure or injunction without further notice if violations are not adequately addressed, a posture consistent with CDER's escalating enforcement posture on sterile drug manufacturers supplying critical intravenous products.

The measurable checkpoint ahead is Fresenius Kabi's formal warning letter response, which will need to demonstrate data-supported root causes, expanded investigation scope, and documented CAPA effectiveness checks across all affected sterile injectable programs at the Melrose Park site.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Warning Letters database, September 29, 2026. Warning letter reference number 320-26-129; inspection FEI 1450022.